Rappel de STALORAL and PHOSTALSTALORAL (range of sublingual solutions of allergen extracts for allergen immunotherapy)

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Stallergenes Australia Pty Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2015-RN-01213-1
  • Classe de risque de l'événement
    Class I
  • Date de mise en oeuvre de l'événement
    2015-12-15
  • Pays de l'événement
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Stallergenes australia is recalling the above medicines shipped from the stallergenes antony (france) plant after august 13, 2015. this decision has been made after identification by the french health authority, ansm that the implementation of a new it system on 13 august 2015 could lead to these medicines having incorrect labelling that could result in incorrect dosing. this issue has also caused operational disruptions and supply shortages. any medicines manufactured before 13 august 2015 are not affected and can be used. if the dosage for these medicines is incorrect, there is a potential for inadequate treatment, excessive dosage and/or allergic reaction. as of 16 december 2015, there have been no reports of adverse events in australia or outside of france associated with this issue.
  • Action
    Stellergenes Australia is advising users to return any unsed stock to the wholesaler for return to Stallergenes. For further information, please see http://www.tga.gov.au/alert/staloral-and-phostal This action has been closed-out on 05/09/2016.

Device

  • Modèle / numéro de série
    STALORAL and PHOSTALSTALORAL (range of sublingual solutions of allergen extracts for allergen immunotherapy) Multiple Product Codes and Lot/batch numbers affectedPHOSTAL (European Dust Mite (D. Pteronvssinus) suspension for injectionProduct Code: 400007276Lots numbers: 2000277946 & 2000577822
  • Manufacturer

Manufacturer